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Cutaneous melanoma is epidemiologically linked to ultraviolet radiation (UVR), but the molecular mechanisms by which UVR drives melanomagenesis remain unclear 1, 2 . The most common somatic mutation in melanoma is a V600E substitution in BRAF, which is an early event 3 . To investigate how UVR accelerates oncogenic BRAF-driven melanomagenesis, we used a BRAF(V600E) mouse model. In mice expressing BRAF(V600E) in their melanocytes, a single dose of UVR that mimicked mild sunburn in humans induced clonal expansion of the melanocytes, and repeated doses of UVR increased melanoma burden. Here we show that sunscreen (UVA superior, UVB sun protection factor (SPF) 50) delayed the onset of UVR-driven melanoma, but only provided partial protection. The UVR-exposed tumours showed increased numbers of single nucleotide variants and we observed mutations (H39Y, S124F, R245C, R270C, C272G) in the Trp53 tumour suppressor in approximately 40% of cases. TP53 is an accepted UVR target in human non-melanoma skin cancer, but is not thought to have a major role in melanoma 4 . However, we show that, in mice, mutant Trp53 accelerated BRAF(V600E)-driven melanomagenesis, and that TP53 mutations are linked to evidence of UVR-induced DNA damage in human melanoma. Thus, we provide mechanistic insight into epidemiological data linking UVR to acquired naevi in humans 5 . Furthermore, we identify TP53/Trp53 as a UVRtarget gene that cooperates with BRAF(V600E) to induce melanoma, providing molecular insight into how UVR accelerates melanomagenesis. Our study validates public health campaigns that promote sunscreen protection for individuals at risk of melanoma.
We expressed BRAF(V600E) in the melanocytes of 2-month-old mice 6 and, 1 month later, protected half of the shaved backs of the mice with a cloth and exposed the other half to low doses of UVR ( Fig. 1a and Extended Data Fig. 1a, b ). UVR upregulates Trp53 (ref. 7) , and, within 24 h of a single UVR exposure, we observed Trp53 staining in ,41% of epidermal keratinocytes and down into the reticular dermis ( Fig. 1b , Extended Data Fig. 1c and Extended Data Table 1 ). We also observed abundant sunburn cells (,17 cells mm 21 ) in the basal layer of the UVRexposed skin ( Fig. 1c and Extended Data Table 1 ). The skin did not blister, but after 24-48 h it developed mild erythema, and after 7 days it was rough to the touch, showed fine desquamation and was thicker due to hyperkeratosis, epidermal hypertrophy and a thickened fibrotic dermis (Fig. 1d ).
UVR induces melanocyte proliferation 8 , and naevogenesis is driven by clonal expansion of melanocytes expressing mutant BRAF, the acquisition of which is an early event 3 . Furthermore, the incidence of acquired human naevi, ,80% of which carry BRAF mutations 9 , is linked to UVR exposure 10 . We show that UVR induced BRAF(V600E)-melanocyte proliferation in vivo in mice (Extended Data Fig. 2 ) and, within 7 days, the UVR-exposed skin had more abundant and larger naevi than non-UVRexposed skin (Fig. 1d , Extended Data Fig. 3a-d and Extended Data Table 2 ). These UVR-induced changes persisted ( Fig. 1e ) and the UVR-exposed skin darkened ( Fig. 1f ). UVR did not induce naevi or skin darkening in non-BRAF(V600E) mice (Extended Data Fig. 3e , f). Thus, we validate human epidemiological studies by showing that BRAF(V600E)-expressing melanocytes are susceptible to proliferation and naevogenesis driven by low-dose UVR that mimics mild sunburn.
As previously reported 6 , BRAF(V600E) induced melanoma in ,70% of mice at a median latency of 12.6 months. On average each mouse developed 0.9 tumours on its back ( Fig. 2a, b ). When exposed to UVR, all BRAF(V600E) mice developed melanoma within 7 months at a median latency of 5.3 months and an average of ,3.5 (range 1-6) tumours each, 98% (59/60) of which were within the UVR-exposed area ( Fig. 2a -c). UVR did not induce melanoma in non-BRAF(V600E) mice ( Fig. 2a ). Thus, we concluded that UVR accelerated BRAF(V600E)-driven melanomagenesis.
The UVR and non-UVR tumours were asymmetrical, predominantly amelanotic and locally destructive ( Fig. 2d and Extended Data Fig. 4a, b ). They invaded the deeper subcutis, showed superficial naevi and pigmented cells, and ,50% ulcerated the overlying epidermis ( Fig. 2e and Extended Data Fig. 4b ). The tumour cells were atypical with dendritic/ plump spindle morphology, and stained positive for S100 and HMB-45/MelanA ( Fig. 2e , f and Extended Data Fig. 4a , c-e). They were heterogeneous, highly mitotic (20 mitoses per 10 high-power fields; 10 tumours analysed) and Ki-67 positive (26.4%, range 10-50; Extended Data Fig. 4a , f).
Application of sunscreen (UVA superior, UVB SPF 50) 30 min before UVR exposure blocked induction of Trp53 and apoptosis in epidermal keratinocytes (Extended Data Fig. 5a -c and Extended Data Table 1 ). These are largely UVB-driven responses 7 , but sunscreen also blocked UVA-induced epidermal hypertrophy and dermal thickening (Extended Data Fig. 5d ). The cloth-protected and sunscreen-protected naevi were indistinguishable and sunscreen prevented UVR-driven skin darkening (Extended Data Fig. 6a, b ). Thus, sunscreen protected the epidermis from the immediate effects of UVA and UVB, but nevertheless all of the sunscreen-protected UVR-exposed BRAF(V600E) mice developed tumours within 15 months at a median latency of 7.5 months ( Fig. 2a ), a significant reduction compared with unprotected mice, but a significant increase compared with non-UVR-exposed mice (P 5 0.03; Fisher's exact test). Sunscreen-protected mice developed ,1.5 tumours on their backs, again significantly fewer than unprotected mice, but significantly more than non-UVR-exposed mice (Fig. 2b, c) . The sunscreen-protected melanomas had similar histology to non-UVR and UVR-exposed melanomas ( Fig. 2d-f and Extended Data Fig. 6c ) and were more common on sunscreen-protected (14 tumours) than cloth-protected (8 tumours) skin. Thus, sunscreen only partially prevented acceleration of BRAF (V600E)-driven melanomagenesis by UVR.
Array comparative genome hybridization (aCGH) revealed no significant differences in gross chromosomal aberrations or copy number variations between non-UVR and UVR melanomas ( Fig. 3a ), but the non-UVR melanomas showed significantly more (60% versus 13.3%) recurrent copy number changes in melanoma oncogenes and tumour suppressors 11 (Mitf, Braf, Ccnd1, Cdkn2a; Fig. 3b and Supplementary  Table 1 ). Whole-exome sequencing (WES) revealed that UVR-exposed melanomas had significantly more somatic single nucleotide variants (SNVs; median 6.16 (range 0.26-40.69) versus 0.19 (range 0.02-2.16) SNVs per megabase pair (Mb); Fig. 3c and Supplementary Table 1 ) and a significantly higher proportion of C-to-T transitions (median 16.7% versus 76.6%) at the 39 end of pyrimidine dimers than non-UVR tumours ( Fig. 3d, e ). This provides direct evidence of UVR-induced DNA damage 12 and, notably, although sunscreen significantly reduced the number of SNVs (median 0.25050 SNVs per Mb (range 0.08233-0.64432)) in UVRexposed melanomas ( Fig. 3c and Supplementary Table 1 ), the tumours still showed a higher proportion of C-to-T transitions at the 39 end of pyrimidine dimers than non-UVR-exposed melanomas ( Fig. 3d, e ). Thus, a UVR exposed (9 w) Protected (9 w) d f UVR exposed (24 h) UVR exposed (7 d) Protected (7 d) UVR exposed (7 m) Protected (7 m) a, Experimental design. b, Trp53 staining (arrows) in protected and UVR-exposed epidermis 24 h after UVR. Scale bar, 50 mm. Five animals were examined. c, Haematoxylin and eosin (H&E)-stained section of protected and UVR-exposed epidermis 24 h after UVR. Arrows indicate sunburn cells (apoptotic keratinocytes). Scale bar, 50 mm. d, H&E stain of protected and UVR-exposed epidermis 7 days (d) after UVR. Arrows indicate dermal naevi; double-headed arrows indicate epidermal-dermal thickness. Scale bar, 500 mm. e, H&E stain of protected and UVR-exposed epidermis 7 months (m) after UVR. Arrows indicate dermal naevi; double-headed arrows indicate epidermal-dermal thickness. Scale bar, 500 mm. f, Protected and UVR-exposed skin 9 weeks (w) after UVR treatments. Original magnification, 32. a, Kaplan-Meier curve showing melanoma-free survival in tamoxifen-treated UVR-exposed CreERT2 mice (CreERT21UVR; n 5 14), BRAF(V600E) mice (BRAF(V600E)/non-UVR; n 5 55), UVR-exposed BRAF(V600E) mice (BRAF(V600E)1UVR; n 5 19), and UVR-exposed sunscreen-protected BRAF(V600E) mice (BRAF(V600E)1UVR1SS; n 5 22 
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sunscreen reduced overall mutation burden but did not completely block UVR-induced DNA damage. We observed Trp53 mutations in 6 of 15 UVR-exposed melanomas, 1 of 11 sunscreen-protected UVR-exposed melanomas, but none of 15 non-UVR-exposed tumours (Fig. 4a , Extended Data Table 3a and Supplementary Table 1 ). We confirmed the Trp53 mutations ( Fig. 4b and Extended Data Table 3a ) and note that there were no significant differences in the number of SNVs in the UVR-exposed Trp53-mutant and Trp53 wild-type tumours (Extended Data Fig. 7a ), suggesting that mutant Trp53 did not contribute to overall mutation burden. The mutations involved codons H39, S124, R245, R270 and C272, and six of seven were C-to-T transitions at the 39 end of pyrimidine dimers (Extended Data  Table 3a ), supporting a direct role for UVR in the induction of Trp53 mutations in melanoma. S124, R245, R270 and C272 are in the Trp53 DNA-binding domain and the corresponding residues (S127, R248, R273 and C275) are mutated in human TP53 in melanoma (Extended Data  Table 3a ), producing deleterious effects that severely impair promoterspecific TP53 transcriptional activity 13 (Extended Data Table 3b ). R273 and R248 are human cancer mutation hotspots and produce proteins with dominant-negative and other gain-of-function activities [14] [15] [16] . Mutations in the amino-terminus of TP53 are rare, and H39 of mouse Trp53 is not conserved in human TP53, but the equivalent residue (Q38) is mutated in human cancer (Extended Data Table 3a ). Notably, all of the mutant proteins accumulated in our mouse melanomas ( Fig. 4c and Extended Data Table 3a ), suggesting common functional consequences.
Two conditional-inducible mouse alleles for DNA-binding-domain Trp53 mutants are available, Trp53 LSL-R172H and Trp53 LSL-R270H . The resultant mutant proteins are functionally similar; they possess dominantnegative and gain-of-function activities, and they accumulate in tumours 16 . The Trp53 LSL-R172H mice were readily available, so we generated heterozygous mice that expressed one copy of Trp53(R172H) in their melanocytes (Trp53 1/LSL-R172H ;Tyr::CreERT2 1/o ). These mice did not develop melanoma, but when crossed to the BRAF(V600E) mice (Trp53 1/LSL-R172H :: Braf 1/LSL-V600E ;Tyr::CreERT2 1/o ), all of the mice developed on average 6 tumours (range 2-10) on their backs within 3.5 months ( Fig. 4d-f ). The tumours presented the histopathological features of other BRAF(V600E)driven melanomas (Fig. 4g , h and Extended Data Fig. 7b ). Thus, as with the deletion of one copy of the tumour suppressor Pten (Extended Data Fig. 7c ) 17 , we show that mutant Trp53 accelerated BRAF-driven melanomagenesis (P , 0.0001; Fisher's exact test).
Finally, analysis of WES data from the Broad Institute 18 , The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/) and Yale University 19 revealed that TP53 mutations coincided with a higher proportion of C-to-T transitions and a UVR signature in primary and metastatic human cutaneous melanomas ( Fig. 4i , Extended Data Fig. 7d and Extended Data Table 3c ). Thus, in human and mouse melanomas, TP53/ Trp53 mutations were associated with UVR-induced DNA damage, establishing that UVR accelerates melanomagenesis by targeting TP53/Trp53.
TP53 is a recognized UVR target in non-melanoma skin cancers, but is thought not to have a role in melanoma, because frequent p14 ARF loss stabilizes HDM2, inactivating TP53 (ref. 4 ). However, we show that ,40% of mouse and ,20% of human melanomas with evidence of UVR-induced DNA damage carried Trp53/TP53 mutations 18 . Trp53 gene deletions can cooperate with BRAF(V600E) to induce melanoma in mice and fish 20, 21 , but in UVR-exposed melanomas TP53/Trp53 is mutated rather than lost, generating proteins with gain-of-function and dominant-negative activities [14] [15] [16] . This suggests a complex role for TP53/Trp53 in melanoma that cannot be accomplished if the protein is lost. Our data establish that TP53 is a bona fide UVR target in melanoma, providing insight into how UVR drives melanoma, albeit through mechanisms that have not yet been elucidated. Mutant TP53 drives tumorigenesis through processes inducing evasion of senescence, activation of autophagy, engagement of DNA-damage responses and oxidative stress pathway reactivation, but individual mutants influence these functions differently. Also, it was recently shown that UVR stimulates melanoma invasion, but the role of TP53 in this remains unknown 22 . Studies are required to elucidate the role of TP53 in melanoma and to identify other UVR targets in TP53/Trp53-mutant and TP53/Trp53 wild-type tumours. Intriguingly, recurrent UVR-signature mutations occur in RAC1, STK19 and PPP6C in melanoma, but their roles in melanomagenesis at present are unclear 18, 19 . It is also unclear what induces BRAF (V600E) because it is not a UVR-signature mutation. Nevertheless, our data show that BRAF(V600E)-expressing melanocytes are susceptible to UVR-driven naevogenesis and melanomagenesis.
In previous UVR melanoma models, embryonic mice constitutively expressed oncogenes, generally with loss of tumour suppressor genes, and 
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the mice received a single burning dose of UVR 1-3 days after birth 23, 24 . In this model melanoma is driven by inflammation mediated by interferonc secreted by neonatal macrophages, and it does not accelerate BRAF (V600E)-driven melanoma 25 . We expressed BRAF(V600E) at physiological levels in adolescent mice without manipulation of tumour suppressor genes and exposed the mice to repeated low doses of UVR. Thus, we mimicked both somatic mutation acquisition and mild sunburn in humans, and our tumours were driven by acquired Trp53 mutations. We therefore reveal two UVR melanoma pathways, one driven by inflammation in neonates and one driven by UVR-induced mutations in adults. It is accepted that sunscreen protects against squamous cell carcinoma 26 , but controversy surrounds its ability to protect against melanoma [27] [28] [29] . The US Environmental Protection Agency states that there is ''no evidence that sunscreens protect you from malignant melanoma'' (http:// www.epa.gov/sunwise/doc/sunscreen.pdf), but we establish that sunscreen delayed UVR-driven melanoma in susceptible mice, validating public health campaigns that promote its use for melanoma. However, sunscreen did not safeguard against UVR completely and we advocate combining it with other sun avoidance strategies, particularly in at-risk individuals with BRAF-mutant naevi 1, 30 .
METHODS SUMMARY
BRAF(V600E) expression and UVR treatments. BRAF(V600E) was expressed in mouse melanocytes by topical application of tamoxifen to the shaved backs of mice at ,2 months of age as described previously 6 ( Fig. 1a and Extended Data Fig. 1a ). One month later, half the back of anaesthetized mice was vertically covered with a UVR-proof cloth, providing an internal contralateral control, and the other half was exposed to 160 mJ cm 22 UVA/UVB using a broad-spectrum UVA/UVB lamp, performing weekly re-exposures for up to 6 months ( Fig. 1a and Extended Data Fig. 1a, 1b) . For the sunscreen protection experiments, mice were treated with Sunsense Milk Sunscreen SPF 50 as recommended by the US Food and Drug Administration (2.2 mg cm 22 ) by topical application 30 min before UVR exposure. Tumour analysis. Mouse genomic DNA was prepared for aCGH and WES as described in Methods. One-hundred and seven randomly selected SNVs were validated by Sanger sequencing to reveal a true positive rate of 93.5%. Tamoxifen (Sigma-Aldrich T5648) was freshly prepared in 100% ethanol. For genotyping, genomic DNA was prepared from tail biopsies and PCR was performed using the primers previously described 6 . Groups of .10 animals per cohort were based on historical precedent to provide statistically significant survival rates in Kaplan-Meier analysis. No randomization or blinding was required. Animals were killed when their tumour burden reached ethical limits, if they showed signs of ill health or distress, or after a maximum of 24 months on the study. BRAF(V600E) expression and UVR treatments. BRAF(V600E) was expressed in female C57BL/6 mouse melanocytes by topical application of tamoxifen to the shaved backs of mice at ,2 months of age. A month later mice were anaesthetized and the whole backs were shaved. Half of the shaved backs were covered vertically with a UVR-proof cloth, to provide an internal control for non-UVR-exposed skin.
Each animal was treated with 160 mJ cm 22 UVA/UVB or 15 J cm 22 UVA (Waldmann UV181 lamps fitted with UV 6 or UV A-1 tubes) each week for up to 6 months. For the sunscreen protection experiments, mice were treated with Sunsense Milk Sunscreen SPF 50 as recommended by the US Food and Drug Administration (2.2 mg cm 22 ) by topical application 30 min before UVR exposure. Histology and immunohistochemistry. For immunohistochemistry, samples were processed as described 6 . Briefly, sections were deparaffinized with xylene and hydrated with a series of graded alcohol washes. Sections were microwaved in citrate buffer (pH 6) for antigen retrieval and rinsed in PBS washes. Sections were blocked in 1% BSA in PBS, incubated with 1:200 dilutions of anti-S100 (Dako), 1:100 dilutions of anti-Ki-67 (Santa Cruz), 1:200 dilutions of mouse anti-HMB-45/MelanA (Abcam), 1:100 Tp53 (Abcam) antibodies. Appropriate negative and positive controls for specificity of staining were included and images were captured using a Leica DM4000 B LED automated upright microscope system. Naevus quantification. For each animal, at least three samples of skin were collected. The skin sections were cut perpendicular to the longitudinal axis of the animals to span the exposed and non-exposed areas of the tamoxifen-treated back. Two independent observers (observers 1 and 2, A.V. and M.C. respectively) performed naevus quantification blinded for animal group. For each animal, naevi were quantified in three different skin sections of 1.8 mm width each of UVRexposed and protected skin. Significance was tested with the WRST. The size of the naevus was measured by a single observer recording the largest diameter for each naevus in 10.8 mm skin of UVR-exposed and non-exposed protected skin and significance was tested using the Mann-Whitney U test. Four animals were scored. Trp53 quantification. We quantified Trp53 by scoring nuclear staining in 500 consecutive keratinocytes for each mouse in UVR-exposed, protected, and UVR plus sunscreen-treated skin. Four animals were scored. Sunburn cell quantification. We quantified sunburn cells in 1 mm of interfollicular basal keratinocytes for each mouse in UVR-exposed, protected, and UVR plus sunscreen-treated skin. Four animals were scored.
Immunofluoresence. Three-millimetre sections of formalin-fixed paraffin-embedded (FFPE) material were used. Slides were dewaxed and antigen retrieval was performed using citrate buffer pH 6 followed by blocking in PBS-Tween 0.1% plus 1% BSA for 15 min and overnight incubation with anti-Ki-67 (Santa Cruz sc-7846) and S100 antibody (1:100 in PBS plus 1% BSA). Antibody detection was performed using AlexaFluor-conjugated secondary antibodies (Invitrogen). Slides were counterstained with 49,6-diamidino-2-phenylindole (DAPI). Samples were analysed and pictures of the mid-dermis were taken using a Leica confocal scanning microscope (Leica Microsystems).
Tumour analysis. Mouse genomic DNA was prepared for aCGH and WES. Onehundred and seven randomly selected SNVs were validated by Sanger sequencing to reveal a true positive rate of 93.5%. WES and aCGH. Seventy-five manually dissected sections of 20 mm snap-frozen tissue samples with an estimated tumour cell percentage of at least 80% were used for DNA extraction. Normal DNA was isolated from liver or kidney. DNA extraction was performed using a DNeasy blood and tissue kit (Qiagen). Quality assessment was performed by NanoDrop and Qubit. For aCGH, 2 mg of normal and tumour DNA were hybridized to Nimblegen HX3 MM9 whole-genome CGH arrays (100718_ MM9_WG_CGH). Normalization, window averaging and segmentation were conducted using the standard Nimblegen aCGH analysis pipeline. The BioConductor package aCGH was used to summarize and plot copy number alterations. For WES, 15 tumours from UVR-exposed areas, 15 tumours from animals not exposed to UVR and 11 tumours from animals exposed to UVR and treated with sunscreen were included. Matched normal DNA samples from liver or kidney were obtained. DNA was extracted from frozen materials. 20) and processSomatic at positions with coverage $10 in the normal tissue and tumour. Likely false positives were removed using predetermined filters 35 . The somatic mutational status of Trp53 in all tumour samples was also verified using Somaticsniper 36 . No mutations in Trp53 in the non-UVR melanoma samples were identified by either method. Somatic variants were annotated by the Ensembl Variant Effect Predictor 37 using Ensembl version 67 and variants present in dbSNP were excluded. For Sanger sequencing validation, genomic DNA was amplified by PCR to confirm selected mutations. The products were directly sequenced using dye-terminator chemistry as previously described 38 . Sequences were visualized using Sequencher software. Primer sequences are available upon request. One-hundred and seven randomly selected SNVs were validated by Sanger sequencing, to reveal a true positive rate of 93.5%. 
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In Fig. 4b of this letter, we made an error transcribing the sequence of the read. The trace itself is correct and demonstrates the presence of the H39Y mutation in Trp53, but the transcribed sequence should have been 'CACCTNACTGC' instead of 'CACCANACATC'. Note, however, that the corresponding sequence in Supplementary Table 3 is correct. Figure 1 of this corrigendum shows the corrected Fig. 4b . 
